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Abstract
Background: Parents of children living with chronic but manageable conditions hope for improved therapies or
cures, including Advanced Therapy Medicinal Products (ATMPs). Multiple pediatric clinical trials for ATMPs are
underway, but the risk profile of ATMPs for chronic conditions is largely unknown and likely different than for
terminal pediatric illnesses. Applying Protection Motivation Theory modified to the context of pediatric ATMP
clinical trial enrollment, our study analyses information needs of parents of children living with chronic manageable
conditions: Type 1 Diabetes (T1D) or Inherited Retinal Diseases (IRD).
Methods: We conducted semi-structured interviews with 15 parents of children living with T1D and 14 parents of
children living with an IRD about: a) family background and the diagnostic experience; b) awareness of gene and
stem cell therapy research and clinical trials for T1D and IRD; c) information sources on trials and responses to that
information; d) attitudes to trial participation, including internationally; e) understanding of trial purpose and
process; and f) any experiences with trial participation. We then discussed a pediatric ATMP clinical trial information
sheet, which we developed with experts. We applied directed qualitative content analysis, based on PMT, to
examine the information preferences of parents in deciding whether to enrol their children in stem cell or gene
therapy clinical trials.
Results: Parents balanced trial risks against their child’s ability to cope with the chronic condition. The better the
child’s ability to cope with vision impairment or insulin management, the less likely parents were to assume trial
risks. Conversely, if the child struggled with his/her vision loss, parents were more likely to be interested in trial
participation, but only if the risks were low and likelihood for potential benefit was high.
Conclusions: Fear of adverse events as part of threat appraisal was the predominant consideration for parents in
considering whether to enroll their child living with a manageable, chronic condition in a pediatric clinical trial of
an ATMP. This consideration outweighed potential benefits and severity of their child’s condition. Parents called for
available safety data and fulsome communication processes that would enable them to make informed decisions
about clinical trial enrolment on behalf of their children.
Keywords: Pediatric clinical trial, Diabetes, Inherited retinal disease, Stem cell therapy, Gene therapy, Risk
communication, Informed consent, Protection motivation theory
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Background
Many parents of children living with chronic but man-
ageable conditions follow research advances, hoping for
improved therapies or cures [1–3]. Experimental therap-
ies include stem cell and gene therapies (collectively, Ad-
vanced Therapy Medicinal Products (ATMPs)). Multiple
pediatric clinical trials for ATMPs are underway for a
range of chronic conditions, and some are receiving
regulatory approvals. Spark Therapeutics, recently by ac-
quired by Roche, received United States Food and Drug
Administration approval for its Leber congenital amaur-
osis gene therapy, including pediatric use [4]. Despite
their promise, the risk profile of ATMPs for chronic
pediatric conditions is largely unknown. This risk profile
is likely different than for terminal pediatric illnesses,
such as hematopoietic stem cell transplantation for acute
lymphocytic leukemia.
As the number of pediatric clinical trials for chronic
pediatric conditions increases, parents question whether
to enroll their children or to access unproven therapies
at for-profit clinics around the world. It is timely, there-
fore, to assess the information needs of parents who are
making health decisions on behalf of their children. We
apply a well-established communication and behaviour
prediction framework, the protection motivation theory
(PMT) (Fig. 1) [5, 6], to analyse how parents use various
forms of information to assess how to best protect an as-
pect of their child’s health or safety. Our qualitative,
interview-based study focuses on parents of children liv-
ing with chronic, manageable conditions: Type 1 Dia-
betes (T1D) and inherited retinal diseases (IRDs). T1D is
managed by way of careful, constant monitoring and re-
sponse to insulin levels with an insulin regimen deliv-
ered by injection or pump; IRDs are managed with
environmental design of home and workspaces along
with supportive aids for progressive visual impairment.
Treatment regimens and/or accommodations for both
T1D and IRDs are accordingly burdensome for children
and caregivers.
Clinical trial outcomes for ATMPs receive significant
media coverage, and media are primary sources of treat-
ment information for patients, caregivers, and advocacy
organizations [2, 7]. However, media coverage often un-
derreports risk and overreports benefits and therapeutic
potential of ATMPs [8–10]. Such coverage may generate
unrealistic expectations for patients and families. For ex-
ample, men living with one IRD, choroideremia, gener-
ally had overly optimistic views of the potential for gene
therapy associated with overly positive media framing of
clinical trial outcomes [8, 11]. Other sources feeding
these views may include informed consent processes, as
potential trial participants or their guardians misestimate
the potential for therapeutic benefit [12], especially in
early, safety-focused Phase 1 trials. Trial participants
often conflate research and treatment and are frustrated
by uncertainties over whether treatments will be avail-
able and affordable in a timely manner, if at all [13, 14].
Slow progress on pediatric ATMPs has led parents to
seek alternatives. For example, frustrated by the slow ap-
proval of the Medtronics artificial pancreas system [15],
waiting parents of children with T1D developed a com-
munity of ‘Health Hackers’ [16]. Under the hashtags
#WeAreNotWaiting and #DIYPS (do-it-yourself pan-
creas system), families created closed loop, automated
insulin delivery systems by sharing open access code
combined with readily available health tracking tech-
nologies, such as mobile trackers and smartphones, to
automate their insulin delivery based on basal rate track-
ing [17]. Open access code is made available by devel-
opers under terms that allow it to be modified and
broadly shared. Such community modification of auto-
mated insulin delivery systems by-passes the regulatory
Fig. 1 Protection Motivation Theory (adapted from Rogers 1983)
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environment for safety and efficacy of medical devices.
Similarly, families seek unproven stem cell “therapies”
for chronic diseases, including IRDs, from unregulated,
for-profit clinics around the world, which market dir-
ectly to consumers (a trend known as stem cell tourism)
[18–20]. Such stem cell interventions have documented
risks, including tumor development, disability, and
death. Three women were recently blinded after receiv-
ing an unproven stem cell treatment, outside of a clinical
trial, for age-related macular degeneration at a Florida
clinic at a cost of 5000 USD per procedure [21]. Media
coverage of family fundraising indicates that the cost for
a child to receive a stem cell treatment at such a clinic
for a chronic condition, including blindness, is in excess
of 40,000 USD [18, 19].
As a result, researchers are advocating for guidelines
to assist clinicians and clinical investigators in effectively
communicating with patients about the risks and bene-
fits of experimental or unproven ATMPs [13, 22, 23]. To
date, studies of clinical trial communications have fo-
cused on fatal and acute pediatric conditions, for ex-
ample in oncology and emergency medicine on how to
deliver informed consent content [24–27], design in-
formed consent forms [24, 28–30], and develop assent
procedures [31]. Our study augments this literature by
focusing on communications about enrolment in
pediatric clinical trials of ATMPs for chronic manage-
able diseases.
Theoretical framework
We relate our findings to the established risk communi-
cation theory, protection motivation theory (PMT) [32].
PMT helps explain information use in protective health
decision-making processes. In this study, we focus on
how parents use information on clinical trials that might
slow or reverse negative health outcomes for their
children who are living with a chronic, manageable con-
dition. The PMT proposes that health protection motiv-
ation depends on a threat appraisal and an assessment
of available options to cope with the threat.
To date, PMT has been used to understand how to en-
courage individuals to take action to avoid contracting
or developing a disease (e.g. vaccination [33], exercise
[34], smoking cessation [35]. In these conventional con-
texts, the threat appraisal is based on three factors: (a)
perceived severity of the consequences of contracting or
developing a disease; (b) perceived vulnerability, defined
as the believed likelihood of contracting the disease; and
(c) maladaptive response rewards, defined as the inher-
ent rewards of not performing the recommended health
protection method. Similar to the threat appraisal, the
coping appraisal process uses three factors to assess
recommended health protection behaviors: (a) response
efficacy, defined as the degree of belief that the
recommended responses will ensure avoidance of the
threat; (b) self-efficacy, defined as the confidence in
one’s ability to perform the recommended behavior; and
(c) response costs and barriers, defined as the perceived
financial, time, or energy-based costs required to per-
form the recommended health protection behavior [32].
Health protection decisions are finalized after assessing
the severity of the threat against the ability to cope with
the threat using the recommended methods. Thus
employing the PMT enables understanding of how indi-
viduals weigh the costs and benefits of different health
protection options to come to final behavioural decisions.
Parental decision-making for enrollment in pediatric
clinical trials for chronic manageable diseases offers a
complex example for the application of PMT. We de-
scribe how our study results informed modifications to
the PMT. The modifications accounted for complexities
in parental decisions about enrolling their children, who
are living with chronic manageable diseases, in clinical
trials for gene therapy and stem cell interventions.
Methods
Participants
Between October 2015 and January 2017, with the assist-
ance of Canadian patient advocacy and research organisa-
tions (Foundation Fighting Blindness; Canadian National
Institute for the Blind; Canadian Deaf Blind Association;
Juvenile Diabetes Research Foundation; Canadian Dia-
betes Association), we recruited 15 parents of children
under 18 years old living with T1D (n = 16) and 14 parents
of children living with an IRD (IRD) (n = 16) across five
English-speaking Canadian provinces (see Table 1). Chil-
dren living with IRDs represented a spectrum of condi-
tions and diseases including Usher’s syndrome (n = 2),
retinitis pigmentosa (n = 3), Stargardt’s macular degener-
ation (3), Leber’s hereditary optic neuropathy (n = 1), reti-
noschisis (n = 2), Leber congenital amaurosis (n = 3), and
achromatopsia (n = 2). The organizations enabled us to re-
cruit at patient-focused conferences/research days by pro-
viding us with information booths to connect with
potential participants directly or by providing study infor-
mation letters in registration packages at conferences that
we could not attend personally. Organizations also in-
formed potential participants of the study via their online
communication channels (e.g. newsletters). Participants
who contacted the study staff provided informed consent
prior to being interviewed.
Data collection
We conducted semi-structured interviews either in-
person or over the phone, ranging from 15 to 70min in
duration (see Additional file 1). Our interview guide first
addressed: a) family background and the diagnostic ex-
perience; b) awareness of gene and stem cell therapy
Brooks and Bubela BMC Pediatrics          (2020) 20:123 Page 3 of 14
research and clinical trials for T1D and IRD; c) informa-
tion sources on trials and responses to that information;
d) attitudes to trial participation, including internation-
ally; e) understanding of trial purpose and process; and
f) any experiences with trial participation. Our interview
guide then asked parents to imagine that a researcher
had approached them to enrol their child in a gene or
stem cell therapy clinical trial. Our goal was not to test
knowledge but to understand the substance and form of
communications preferred by the parents. The questions
allowed us to probe participants’ experiences with diagno-
sis and disease management and how communication of
experimental or unproven treatments could be improved.
Finally, we presented the parents with either an infor-
mation sheet for either a pediatric clinical trial of a stem
cell therapy for T1D or a gene therapy for IRD, as ap-
propriate (see Additional file 2). To ensure accuracy, we
collaborated with clinical investigators on trials that
were underway or planned in adults at the University of
Alberta: An Open Label Clinical Trial of Retinal Gene
Therapy for Choroideremia (NCT02077361) and Stem
Cell Mobilization (Plerixafor) and Immunologic Reset in
Type 1 Diabetes (T1DM) (NCT03182426). The informa-
tion sheets addressed the trial background and purpose;
and described the procedure; possible benefits; possible
risks, including surgical risks; confidentiality; voluntari-
ness of participation; and costs of and compensation for
participation. The interviewer reviewed the information
sheet with the parent and recorded all questions, concerns,
reactions, and terms or concepts that required clarification.
Data analysis
We used NVivo 11 qualitative analytic software to
organize, manage, and analyze verbatim transcripts of
the audio recorded interviews. We applied directed
qualitative content analysis, based on the PMT, to exam-
ine the information preferences of parents in deciding
whether to enrol their children in stem cell or gene ther-
apy clinical trials. Directed content analysis is a common
approach to healthcare research [36] in which transcripts
are coded both deductively and inductively to test if/how
data fits into existing theories or models [37, 38]. We
started the study deductively coding transcripts using
coding categories derived from the PMT. Deductive cod-
ing allowed us to examine similarities and differences
between our participants and existing literature. We
augmented our deductive coding with inductive coding,
using a constant comparison approach [39] by immedi-
ately coding each interview transcript, adding new codes
to the coding frame, and using the modified coding
frame to review subsequent interviews, and re-analysing
the already coded transcripts for the new codes.
To assess reliability of our analysis, a second investigator
reviewed the codes to ensure that they comprehensively
Table 1 Characteristics of parents of children living with Type 1
Diabetes (T1D) or an inherited retinal disease (IRD) and
characteristics of their children living with T1D and IRD
Parent Characteristics Number of Parents
T1D IRD Total
Number of children in parent family living with T1D or an IRD
1 14 12 26
2 1 2 3
3+ 0 0 0
Total 15 14 29
Number of years parenting a child living with T1D or an IRD
< 1 2 1 3
1–4 8 7 15
5–7 1 1 2
8–10 2 2 4
11–13 1 3 4
14–17 1 0 1
Total 15 14 29
Prior family history of T1D or an IRD
Yes 4 3 7
No 11 11 22
Total 15 14 29
Province of residence
Alberta 6 5 11
British Columbia 0 1 1
Northwest Territories 0 1 1
Ontario 9 6 15
Saskatchewan 0 1 1
Total 15 14 29
Child Characteristics Number of Children
T1D IRD Total
Children’s age at time of interview (years)
Under 5 3 1 4
5–10 4 6 10
11–17 9 9 18
Total 16 16 32
Children’s age at diagnosis (years)
Under 5 9 10 19
5–10 5 5 10
11–17 2 1 3
Total 16 16 32
Brooks and Bubela BMC Pediatrics          (2020) 20:123 Page 4 of 14
captured the key themes. We also conducted a member
checking exercise [40]. We constructed a summary report
for each interview and returned this to the parent to re-
view the summary and return any comments, add or sub-
tract material or ask additional questions. We integrated
comments into the final analysis.
Results
Modified protection motivation theory (PMT)
Using the directed content analysis method, we modified
PMT to account for the context of ATMP clinical trials
for chronic, manageable, pediatric conditions (Fig. 2).
Our deductive coding enabled us to identify interview
data aligned with existing PMT constructs. Our induct-
ive coding then allowed us to modify PMT to better rep-
resent the constructs in a clinical trial context (e.g.
‘maladaptive response’ became ‘the case for not enrol-
ling’) (Fig. 2).
We added two additional constructs to explain nuanced
dynamics in parental decision-making. These were hope
and fear and their effects in the adaptive response. In a
clinical trial context, the threat appraisal makes the case
for not enrolling in a clinical trial. The child continues to
live with T1D or an IRD and does not assume the risks as-
sociated with clinical trial participation. The coping ap-
praisal makes the case for enrolling in a clinical trial,
based on potential benefits weighed against potential risks
and logistical barriers. Parents simultaneously conducted a
threat appraisal and a coping appraisal when considering
the potential risks and benefits of clinical trial participa-
tion for their children (Fig. 3).
The interviewed parents used available information to
evaluate the benefits and risks of clinical trial enrolment
for their child, and which decision was in the best inter-
ests of their child. Below, we provide illustrative quotes
for each construct of the modified PMT, starting from
‘Sources of Parents’ Pre-Existing Knowledge’ and ending
with their ‘Final Decision’.
Sources of parents’ pre-existing knowledge
Parents in our study were familiar with research on rele-
vant gene and stem cell therapy research. Parents of
children with T1D followed research on, islet encapsula-
tion (n = 9), the artificial pancreas project (n = 7), and
islet transplantation (n = 2). Parents of children living
with an IRD reported following research on stem cell
transplants (n = 7), gene therapies (n = 7), drugs (n = 4),
CRISPR Cas9 (n = 2), bionic eye devices (n = 1), and
homeopathic techniques (n = 1). Some parents were very
active information gathers following a variety of infor-
mation sources including news print, television and on-
line news media and health providers. They often
followed research foundation newsletters, such as those
from Juvenile Diabetes Research Foundation or Founda-
tion Fighting Blindness. Some also participated in online
parent groups on Facebook or other social media
platforms.
I follow a bunch of different kinds of organizations,
groups and companies, the likes of Facebook, and
the news and things. We read anything that pops up
on things like the T1D page or [Juvenile Diabetes
Research Foundation] page. We’re reading all the
Fig. 2 Protection Motivation Theory Constructs Aligned with Clinical Trial Contexts
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news releases and articles to see what’s in the pipe-
line, what people are looking into. – T1D
All had followed research news on their child’s condi-
tion, but some reported that they currently do not follow
any research news (n = 3).
I searched like crazy after [my child’s] diagnosis. But
honestly, I haven’t lately. I hear about things being
planned but I kind of feel like it’s far away and it’s
not something that’s realistic for the population
right now. I’m just kind of waiting for to hear, I
guess mainstream news. – T1D
Finally, seven parents said they had past experiences
that informed their understandings of T1D or IRDs by
way of family members or friends (Table 1). While other
parents were surprised by their children’s diagnoses,
those with past experiences had optimistic views of dis-
ease management derived from evidence of coping by
family members.
Because of the family history, we were comfortable
because his – a couple of his uncles actually do have
it … we talked to [his uncle] and he has had a very
successful business in Saskatoon and he does well in
life. He has had 4 children … you do have an im-
pairment but you’re still functional, right? – IRD
[The diagnosis] was tough but it was not end of the
world because my sister at [her diagnosis] was 20
and obviously had led a normal life. She had some
episodes where she ended up in the hospital but she
has no complications from it as of yet. So I think
that that helps … I remember when my sister was
diagnosed my folks were devastated because we did
not know anything about [diabetes] and nobody else
had had it... whereas, at least I had a good support
network and it was already in the family. – T1D
However, the parents did not have specific knowledge
of our hypothetical trials of ATMPs for T1D and IRDs,
respectively.
Clinical communications
Prior to reading the clinical trial information sheets,
most parents did not understand the clinical trial
process, nor did they have a clear understanding of pre-
clinical and clinical research on the ATMPs. They re-
quired explanation before being able to discuss the
evidence in support of clinical trials. While reading
through the hypothetical ATMP clinical trial informa-
tion sheets, parents asked for clarification on procedures,
risks, and benefits. After reading the sheets and asking
for clarification, parents were able to clearly explain
these topics to the interviewer. Notably parents under-
stood the difference between proven and unproven,
between experimental and treatment, and could distin-
guish between hope and expectation.
I would want to know the purpose, are they giving
them a really low dose? Is it just sort of a safety
dose? Should we now expect to see any improve-
ment or are they giving them the dose that they de-
termine to be the most effective and be best results?
– IRD
I understood that it was kind of experimental or a
trial … It wasn’t tried, tested, and true. Because we
use the words “trial” or “experiment”, I wasn’t
Fig. 3 Modified Protection Motivation Theory in the Context of a Clinical Trial
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optimistic about it... I went into it without expect-
ation. – IRD
While parents generally started the interview optimis-
tic about the potential for ATMPS, they often became
less enthusiastic when they learned about the risks of
trial participation.
So it’s a little bit scarier when you read [the infor-
mation sheet] for sure. I mean I am more hesitant
now than I was 20 min ago. – T1D
Okay. Oh my god. I do not know. There is one part
that sounds yes exciting, like they could do it. But
when I start reading the risks and all these things
and everything, I do not like that part at all. – IRD
I do not know [whether I could say yes or no]. After
reading the sheet it fully kind of changes my mind,
make me hold on for a sec … I could not enter right
now. I would have to really think about it and defin-
itely talk to more professionals and really give it a
lot of thought. – T1D
The case for not enrolling: the threat appraisal
The case for not enrolling encompasses the elements of
the decision-making process that may result in the child
continuing to live with a chronic disease while not as-
suming unjustifiable trial risks.
Advantages of not enrolling
Parents considered the advantages of not enrolling in the
clinical trial, including not assuming trial risks or waiting
for ATMPs with a greater safety profile, even if waiting re-
sulted in continued deterioration of vision or vigilant insu-
lin testing and management. Almost all parents were
uncomfortable with enrolling their child in a first-in-
human clinical trial but might have considered a later
stage trial with a pediatric safety and or efficacy profile.
We have always said that we don’t want our child to
participate in early stage trials. We want it to be
pretty much a sure thing before we subject our child
to something. – IRD
I definitely would not want him to be one of the
first people … If it had been tested on other, maybe
not even people, I hate to say, “Oh, someone else’s
kid has to test it out before mine” because that is
obviously selfish because somebody has got to step
up, but I would have to assess the risks. – IRD
Severity of and vulnerability to T1D/IRD
Parents used available information to assess the severity
of the T1D/IRD against their child’s vulnerability or
probability of experiencing severe consequences that
have consequences for their wellbeing. The child’s ability
to cope with the disease is what dictates whether assum-
ing trials risks are justified.
I would rather maintain [my son’s] current eye sight
rather than take a risk of losing all of it. He knows
how to live with what he has now, so if we could
maintain that forever I think we would be OK. He
hates it, but he knows how to survive. – IRD
I think we’re managing a condition that’s is manage-
able and the risks are real, they’re known and largely
controllable. And I think you would be trading that
for known but uncontrollable risk. So that doesn’t
seem like a fair trade off. – T1D
Similarly with established PMT constructs, fear in-
formed both how parents considered disease severity
and the ability to cope with the disease. The progressive
nature of many IRDs caused fear among parents because
there is a therapeutic window within which to try experi-
mental treatments that may slow, halt or reverse vision
loss. The threat of diabetic coma or long-term impacts
of diabetes caused distress among parents.
“We check their glucose levels every night at mid-
night then again at 3 am … They’re on pumps now
but we had a scenario 6 years ago … in theory we
should not have had to check them … but I woke
up at 4 am and checked and they were both at [dan-
gerous lows]. And so there was no rhyme or reason
… and so we decided at that point, it didn’t matter
what equipment they were on, we would be check-
ing them.” – T1D
The case for enrolling: the coping appraisal
Potential trial benefits
Parents made clear that they were only interested in tri-
als that were likely to provide direct therapeutic benefits.
Parents were not interested in trials designed with pla-
cebo arms, because of wished for benefit in exchange for
assumption of risk.
I would not want to get heavily involved in a trial
where my kids might be on the placebo end of
things, and I know that sounds ridiculous … There’s
a really limited timeframe, you know, for the next
few years and knowing the amount of time that it
takes for research projects to progress, they don’t
have time to waste, being the control arm. – IRD
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In ophthalmic clinical trials, the design may involve a
treated eye and a control eye in the same participant
[41]. Parents acknowledged that this trial design reduced
risks, but also perceived that the potential benefit was
halved if the control eye was left untreated.
Well, I would assume that if it was safe after a cer-
tain amount of time that they would say “Hey,
you’re up for the other eye now.” That is what I
would assume would happen. I would not assume
that they would just leave you if it worked and after
a certain amount of time. – IRD
I like that. I like that. Assuming that you could get
the other eye treated after. – IRD
Similarly, parents were concerned about reversible
treatment for T1D (e.g., devices or implants that would
be tested and removed at the end of the trial). Some par-
ents appreciated that if beneficial, the implant could po-
tentially give their child a period of normalcy during
their childhood. Others were uncomfortable with revers-
ing the treatment if it proved beneficial.
They stop the treatment after 3 years regardless of
how well it’s working? My heart dropped there …
once you see that benefit, you want to keep seeing
benefit. – T1D
Hope
Hope informed the appraisal of potential trial benefits
but was viewed by parents as a double-edged sword. Par-
ents found hope to generate good feelings and to be a
helpful coping tool,
I am just thinking from the other view - you want
to kind of temper people’s expectations, but from a
parent’s point of view, we want hope. – IRD
I mean we have talked to [my son] about it too and
he’s like, “Well, yeah I get it Mom but, you know
what happens if it works?” [and I said to him] “But
you know there is a lot of risks involved.” [and he
replied] “Yeah, I know but that’s okay but what hap-
pens if it works?” – IRD
However, parents also recognized the pain of false
hope and they did not want to inflict false hope on to
their children by accident.
Interviewer: So, you have never talked about trials
with your daughter?
Parent: No. Because I do not want to get her hopes
up … I do not know if she fully understands her
condition yet, but I do not want to plant that seed
because I do not even know if this ever could hap-
pen. – IRD
[Learning about CRISPR] felt other worldly and I
felt like it was too good to be true … I felt very, very
hopeful, but I was also somewhat skeptical … and
fearful because I did not want our hope to be raised
up and our child hopes. We never mentioned it to
[my son]. – IRD
It’s more about managing emotional risks than
physical ones in some ways. I’m not willing to take
a try-anything-and-everything-approach, because
[my son] could be set up for heartbreak. – T1D
Logistical barriers
Logistical barriers may prevent clinical trial participa-
tion. Determination to overcome logistical barriers is in-
fluenced by perception of likelihood and magnitude of
potential benefit. Only one parent stated that logistics
would be a barrier to trial participation. All others stated
the intention to do anything if the magnitude and likeli-
hood of benefits were high enough.
Well, I could and would if I was committed to the
process, like I am not committed to the process at
the moment. So I cannot say ‘I will’ but I could, yes.
And I would if that was what was – I was commit-
ted to do for my daughter, yeah. I would go to the
end of the earth to help her. – IRD
If there was something out there and someone says,
“Hey, you know what for a million dollars I can fix
your son guaranteed 100% no side effects,” right? If
I don’t have it, I’ll work my ass off until I bleed in
order to get that surgery for my son. So that he can
have the best life possible. That is when I would
step up and do whatever to get there. But to put risk
on him, that is a whole different ball game. – IRD
I would pay anything. I don’t care where it is or
how much it is. I would have paid to go find it. Like
if my son can be cured of T1D, I would pay for it
today. I don’t care how much it is. I can find it. –
T1D
Trial risks – physical
Parents were realistic about the potential risks of ATMP
clinical trials, including loss of vision, need for immuno-
suppressant, disqualification from future research or
treatment, child suffering, tumor development, lack of
long-term data, high drug use requirements, and diabetic
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ketoacidosis. While fear is not normally associated with
PMT’s ‘response costs’ construct, it is present in trial
contexts as the experimental intervention is inherently
risky. Given the risk and associated fear, parents wished
to make the best decisions on behalf of their child and
avoid potential guilt for making a poor decision.
… but permanent loss of eyesight, as soon as they
are telling me this, that’s probably the big turn off
that I would say no. Like no. Probably I would never
forgive myself if she went into surgery and then she
lost whatever she has left. I would never forgive my-
self ever. – IRD
… if there is a side effect that could cause problems,
I could never put my child through that. I could
never be that guy and be like oh I was that parent
that said, “Yeah” and now, now this has happened. I
could never live with myself. – IRD
I don’t really want to take any risks, anything that’s
going to hurt him any further because God forbid
with some other things that I should do something
that makes him lose more of his vision. – IRD
How do you - If you made matters worse, you
know, how do you explain that to your child and
live with yourself and so on? So that was the kind of
thinking that was going on in my head. – T1D
Trial risks - opportunity costs
Almost every parent commented that trial participation
may exclude their child from being eligible for future tri-
als or approved treatments.
One of the things is that if she participated in this
study then that might preclude her from doing
other studies. So I guess I would want to know what
other studies are being done and what you foresee
as how the study rates against the others for suc-
cess. Because then I might want to wait for another
study as opposed to participating in this one. – T1D
Protection motivation
Protection motivation is the outcome of assessing the
threat and coping appraisals. These appraisals enable
parents to decide whether they are more motivated to
protect their children from disease severity or from trial
risks. In other words, parents balanced trial risks
against their child’s ability to cope with the chronic
condition. The better the child’s ability to cope with vi-
sion impairment or insulin management, the less likely
parents were to assume trial risks. Conversely, if the
child struggled with his/her vision loss, parents were
more likely to be interested in trial participation, but
only if the risks were low and likelihood for potential
benefit was high.
Final decision and information required for informed
consent
Parents called for complete information about risks, ben-
efits and uncertainty to help them make decisions about
safety and efficacy trials of experimental ATMPs.
I was really excited about it at first. I still am. I’m
still very excited about it. Of course, there’s always
the worries. Will it make it worse? There’s always
that. What are the repercussions of it? What will
happen if he was one of those people that doesn’t
respond to it correctly or that kind of thing? – IRD
Most parents expressed a preference to talk to the lead
clinical researcher before making an enrollment deci-
sion, but there was no expectation that the clinical lead
be the first person to contact the families nor the person
to lead the informed consent process. First, parents
wanted to speak directly to the research lead to clarify
the risks and uncertainties for their child.
I have always appreciated that [my daughter] was
present when information was given … then I don’t
have to re-explain it or give my twist on it … I’ve al-
ways been thankful that she has been present so
that she hears what I hear and then we make deci-
sions. – IRD
I would want to talk to the actual doctor that’s been
doing this to find out, because I’m not a medical
professional, I would want to know what type of
risks could be possible in children. I know that they
have not studied it in children and they can’t say for
sure … but I would need to hear the ways that the
body grows and what having a device in there may
or may not do. – T1D
I think an assistant is the first. I think that is fine. I
think that is a fine first contact but ultimately, I
want to talk to the lead researcher. – IRD
Second, parents felt that their child needed to trust the
clinical research lead and feel comfortable with the re-
search team before the parents would consent to the
research.
I would want the option to bring him in and have
him – again have the opportunity to see where the
procedure would take place and meet the doctors
and to be comfortable. – T1D
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Parents’ request for their children to meet the clinical
research lead was related to their desire to include their
children in the decision-making process. Most parents
wished to include their child in the final decision or to
have the child make the decision.
I would have to talk to him really seriously. My yes
is dependent on his yes. – T1D
[My son], he does have a lot to say. He would have
a lot of influence on any decisions … I would want
the person running the trial, because I’m a parent
who makes sure that [my son] is always in the room
so he can ask as many questions as he could. Be-
cause it is his body. – IRD
I think that those conversations would happen at
every age at the point they can understand … I don’t
know. But at 4, he certainly can be involved in deci-
sions, like “this is going to happen, how do you feel
about it? Do you feel strongly about it?” Okay, if so
we’re probably not going to proceed. – T1D
Many parents expressed the need for a second opinion
before making any final decisions, in some cases from
spouses or trusted family members, in others from their
child’s health care provider. Many also wished to speak
with prior trial participants to gain a more holistic un-
derstanding of the experiences they could expect for
their children.
Talking to the actual patient you could say, “Well,
yeah that it hurts but it was worth the hurt because
I was able to do this.” Where I do not think doctors
are able to really say that unless they are actually
going through it right? – T1D
100% I would want to talk to the doctors perform-
ing the research. Then anyone else going through it,
in the trial … some who’s actually living the experi-
ence … some type of opportunity to listen face-to-
face, because it is one thing to read it and another
to engage in the discussion. – T1D
Absolutely, [my son], I would want him involved as
well as my husband. And maybe my dad. He’s a big
science guy so I think he would maybe hear some-
thing different than me as a parent. Where he
would be a little more objective more maybe more
cautious. – IRD
Treatment tourism
Most of the parents would not enable their child to re-
ceive unapproved therapies outside of the context of a
credible clinical trial, including in a country with lower
regulatory standards than North America or Europe.
No. I mean, yeah, obviously, the credibility of the
researchers— It kind of goes along with the chances
of this being actually successful. You have to trust
the researchers. You don’t have time to waste on
something that’s not credible. – IRD
No, if we are talking about China, no. Because I just
find that their ethics are not up to my standard and
I think they just do things too quickly and yeah, no.
I would stick to Canada. – IRD
You do not go online and type in ‘diabetes research’
because you get all kinds of crap and I am not going
to Mexico for some weird clinic, some alternative
therapy. I’m just not … It’s too Cracker Jack for me.
If [my son] was going to participate in a trial, there
would have to be some evidence that supported suc-
cess. – T1D
However, one parent had taken her son overseas for
an unproven homeopathic treatment, after engaging in
the same decision-making process that involved both
threat and coping appraisals as described above. The
parent of a child with an IRD felt hopeless because there
was no treatment available in North America. Online,
she found a clinic that represented it could cure her
son’s condition through patient testimonials.
When we looked on the website, they said it’s per-
manent, there was no risk they have been doing it
for so long and then like I said, I talked to patients.
I found them on the website or on Facebook and I
contacted them and that is when we talked to pa-
tients … They had good results, that is when we, we
felt comfortable, like nerve wracking but no pain
and that stuff for the child. That is when we felt
like, my son is not the only one, there’s a lot like
him. [The clinic] has been doing it from 2001 and
there is nothing but amazing comments. – IRD
Her son’s clinician in Canada did not explain any risks
that might have tempered the positive framing on the
clinic website and conversations with past patients.
I did talk to [my clinician’s] specialist, and she said
“Well, I cannot say yes and I cannot say no. That’s
your decision. We don’t know about [the clinic].”
And there is pretty much no cure, so who else am I
going to talk to? – IRD
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In her view, she felt her son’s vision improved after
the treatment, and she submitted this result to the pro-
vincial government. She was frustrated that Canada
would not approve the treatment and was confused and
frustrated that the Province found there was insufficient
evident to pay for the treatment.
However, when presented with information about the
risks and benefits of ATMP clinical trial enrolment, she
demonstrated the same hesitancy as other parents.
For me honestly, I would be scared to put my child
into this clinical trial … because it is saying it is an
operation, right? That will inject fluid under the ret-
ina. I do not know, if it was to be after the treat-
ment in the clinical trial was approved then I would.
– IRD
Discussion
Using the modified PMT, our results, when compared to
those of other studies, demonstrated distinctions in
decision-making processes between: a) preventative and
treatment behaviors; b) acute/fatal diseases and chronic
manageable conditions; and c) personal decisions versus
those made on behalf of someone else. Protective behav-
iours studied in health contexts are most commonly
those to detect diseases (e.g. breast cancer screening), to
adopt health practices (e.g. following an exercise regi-
men), or to cease unhealthy behaviours in response to
acute or reversible disease threats (e.g. smoking cessa-
tion) [42, 43]. Clinical trial enrollment decisions are dif-
ferent in a number of fundamental ways.
Seeking treatment in general is an understudied be-
havior in PMT research [43]. To our knowledge, this is
the first study applying PMT for those seeking experi-
mental interventions. Furthermore, PMT literature often
focuses on decisions to take up safe and healthy alterna-
tives to poor existing health behaviours. Participants in
our study viewed clinical trial enrollment is a potential
alternative to living with T1D or and IRD but recognized
the risks involved in experimental interventions.
Normally, response costs (trial risks in our PMT modi-
fication) represent beliefs about how costly performing
the new protective behavior will be [42] (e.g. energy re-
quired to perform an action, comfort disclosing health
information), however they are not normally risky them-
selves. Normally PMT is applied to situations where a
person can continue with an unhealthy behavior or
adopt a healthier path. Clinical trial contexts present a
case for decisions between two risky paths containing
uncertain outcomes. This is an exceptionally difficult
type of decision to make on someone else behalf, espe-
cially when physical safety is at risk [44], as was the case
for the parents in this study.
Parents relied on existing values and knowledge in
making health-related decisions on behalf of their chil-
dren. They desired complete information on risks and
potential benefits before making any clinical trial enroll-
ment decisions. Parents’ approach to decision-making
reflected the nature of their children’s manageable,
chronic conditions. Similar to other studies, our parent
participants were prepared to carefully consider accept-
able risks weighed against benefits [45, 46]. Parents in
our study frequently articulated that their children were
coping with their conditions, making decisions to enroll
in clinical trials harder to justify.
Application of PMT to pediatric clinical trials for chronic
manageable conditions
The threat appraisal informed the case against enrolling
in a trial. Considerations included protecting a child
from further discomfort or harm and waiting for more
evidence of safety and efficacy before making a decision
on behalf of a child. This intention to wait for better evi-
dence contrasts with prospective adult clinical trial par-
ticipants, who have little recognition and appreciation of
risks and disadvantages of trial participation [47], suffer
from therapeutic misconception [14], and overestimate
potential benefits [48] when signing consent forms.
However, parents are often anxious about their child
being treated as a ‘guinea pig’ [26] and fear making the
‘wrong’ decision [49].
Under the PMT model, vulnerability relates to the
probability of contracting a disease or condition if a be-
haviour is left unchanged. In our study, vulnerability re-
lated to the impact of the condition on the child’s
quality of life. While parents hoped for improved therap-
ies, their primary interest was to protect their children
from further negative health and life impacts. Parents of
children living with T1D sought to protect their chil-
dren’s experience of childhood with treatments that im-
proved diet, sleep, and need for insulin injections.
Parents of children living with IRDs sought to protect
the remaining vision of their children.
With respect to the coping appraisal, parents were re-
ceptive to considering the potential benefits of trial par-
ticipation for their children, with primacy given to
therapeutic benefit not altruism. Indeed, the hope for
therapeutic benefit led one mother to engage in treat-
ment tourism for her child [19, 20]. The ability to over-
come logistical barriers is understood as a key
component in all major health behavior models, includ-
ing PMT [50], but our results suggest that, in a trial con-
text, strong beliefs that the trial will create benefit
negate logistical considerations. Other benefits not iden-
tified by our participants include free medication, better
care of their child, and greater access to healthcare pro-
fessionals and health information [45].
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Implications for pediatric clinical trial consent process
Contrary to concerns that parents may suffer from
therapeutic misconception or unrealistic optimism [51,
52], our participants differentiated between hope and ex-
pectation. To facilitate this differentiation, pediatric clin-
ical trial consent processes must provide complete
information, including about: a) the scientific process
and understanding uncertainty; b) maximum therapeutic
potential; c) magnitude and likelihood of all benefits and
risks; and d) approved and available supportive or treat-
ment regimens. The need for transparency and com-
pleteness of information are compounded by trust
relationships – mothers of children involved in diabetes
research assumed benefits as they could not “imagine
honorable nurses or physicians putting their children at
risk” [53].
Our findings support the need for guidelines on com-
munications about enrolment in legitimate pediatric
clinical trials [13, 22, 23]. Such resources are available
from research and patient organizations (e.g., Founda-
tion Fighting Blindness [54] and International Society
for Stem Cell Research [55]) and can help health care
providers discuss clinical trial processes, expectations for
therapeutic developments, realistic timelines, and how to
identify legitimate clinical trials compared to unproven
treatment tourism options. Communications should
modulate expectations, while maintaining hope [13].
Similar to other studies, our parent participants add-
itionally expressed the wish to contact prior participants
to help inform their decisions [30, 45]. Such a practice
could be permissible with consent of the participants to
be contacted; however, it comes with a risk of misinfor-
mation and selection bias, which may distort the norm
towards positive or negative experiences. Parents add-
itionally suggested that they would like to discuss clinical
trial participation with the clinical investigative lead, ra-
ther than with their physicians or other trial staff [42].
This is contrary to best practice, which insulates clinical
investigators from consent processes in case of undue
pressure on potential participants ([56], Article 3.1 (Un-
due Influence)).
Study limitations
Our study included only participants from English-
speaking Canadian provinces, with overrepresentation
from Alberta and Ontario. Our recruitment biased our
population towards those connected in-person or online
to patient advocacy organizations. Our sample size did
not enable us to distinguish parents’ responses based on
the current age, age of diagnoses, time since diagnosis,
and severity of the condition of their child. We con-
ducted individual interviews with parents not with family
units, including the children. Decisions to participate in
clinical trials are unlikely to be made by individual
parents. Further, we recruited participants who had a re-
lationship with patient advocacy organizations; thus par-
ticipants likely had an interest in clinical research and
their views may not be representative of a general popu-
lation of parents.
We reviewed clinical trial information with parents in
a hypothetical context, which may not have elicited a full
range of reflections. Our study did not follow up with
parents and therefore could not assess duration of un-
derstanding on the risks, benefits, uncertainty, and
process they articulated during the interview. Other
studies recommend either an ongoing informed consent
process or multiple meetings that revisit the risks and
benefits prior to final consent for participation [57, 58].
Conclusion
Novel ATMPs lack a strong evidence base of benefit and a
well-characterized risk profile. However, expectation for
benefit is high and public information sources often over-
state benefits relative to risks. This places an onus on clin-
ical investigators to engage in best communications and
consent practices, especially in the context of pediatric
clinical trials. Our results suggest that fear of adverse
events as part of threat appraisal was the predominant
consideration for parents in considering whether to enroll
their child living with a manageable, chronic condition in
a pediatric clinical trial of an ATMP. This consideration
outweighed potential benefits and severity of their child’s
condition. Parents called for available safety data and ful-
some communication processes that would enable them
to make informed decisions about clinical trial enrolment
on behalf of their children.
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